Name | Number of supported studies | Average coverage | |
---|---|---|---|
erythroblast | 6 studies | 44% ± 22% | |
erythrocyte | 6 studies | 50% ± 26% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 45% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 87% | 9.89 | 2308 / 2642 | 26% | 0.44 | 180 / 705 |
spleen | 99% | 188.49 | 239 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1237.89 | 920 / 929 | 0% | 0 | 0 / 0 |
lung | 92% | 27.78 | 529 / 578 | 1% | 0.01 | 12 / 1155 |
muscle | 75% | 12.85 | 605 / 803 | 0% | 0 | 0 / 0 |
liver | 72% | 14.83 | 163 / 226 | 2% | 0.05 | 8 / 406 |
thymus | 64% | 5.41 | 420 / 653 | 2% | 0.03 | 12 / 605 |
lymph node | 0% | 0 | 0 / 0 | 66% | 1.23 | 19 / 29 |
prostate | 55% | 3.57 | 135 / 245 | 1% | 0.02 | 5 / 502 |
breast | 52% | 3.64 | 239 / 459 | 2% | 0.04 | 25 / 1118 |
kidney | 52% | 7.31 | 46 / 89 | 2% | 0.11 | 21 / 901 |
ovary | 34% | 1.88 | 62 / 180 | 13% | 0.24 | 58 / 430 |
adipose | 48% | 4.45 | 575 / 1204 | 0% | 0 | 0 / 0 |
bladder | 43% | 2.14 | 9 / 21 | 2% | 0.05 | 11 / 504 |
stomach | 40% | 2.06 | 143 / 359 | 4% | 0.10 | 12 / 286 |
intestine | 40% | 2.42 | 388 / 966 | 2% | 0.04 | 13 / 527 |
esophagus | 36% | 2.38 | 522 / 1445 | 3% | 0.05 | 5 / 183 |
skin | 35% | 1.83 | 626 / 1809 | 4% | 0.10 | 18 / 472 |
heart | 37% | 3.43 | 320 / 861 | 0% | 0 | 0 / 0 |
pancreas | 36% | 2.05 | 118 / 328 | 1% | 0.01 | 1 / 178 |
blood vessel | 36% | 2.64 | 482 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 32% | 1.84 | 83 / 258 | 3% | 0.18 | 7 / 230 |
uterus | 28% | 1.53 | 47 / 170 | 5% | 0.07 | 22 / 459 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.04 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1901653 | Biological process | cellular response to peptide |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0031648 | Biological process | protein destabilization |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0060135 | Biological process | maternal process involved in female pregnancy |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005515 | Molecular function | protein binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043130 | Molecular function | ubiquitin binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
Gene name | KLF1 |
Protein name | EKLF Krueppel-like factor 1 Truncated erythroid Kruppel-like factor 1 Erythroid Kruppel-like factor 1 variant Krueppel-like factor 1 (Erythroid krueppel-like transcription factor) (EKLF) KLF1 Truncated Kruppel-like factor 1 Truncated EKLF Truncated erythroid Kruppel-like factor EKLF/KLF1 |
Synonyms | EKLF |
Description | FUNCTION: Transcription regulator of erythrocyte development that probably serves as a general switch factor during erythropoiesis. Is a dual regulator of fetal-to-adult globin switching. Binds to the CACCC box in the beta-globin gene promoter and acts as a preferential activator of this gene. Furthermore, it binds to the BCL11A promoter and activates expression of BCL11A, which in turn represses the HBG1 and HBG2 genes. This dual activity ensures that, in most adults, fetal hemoglobin levels are low. Able to activate CD44 and AQP1 promoters. When sumoylated, acts as a transcriptional repressor by promoting interaction with CDH2/MI2beta and also represses megakaryocytic differentiation. . |
Accessions | A0A0U4DAW6 B9UZC6 B9UZC7 A0A0U4D3U3 A0A0U4EBD4 B9UZC3 B9UZC4 A0A0U4CJG7 Q13351 K7VKE0 A0A1U9WYY8 A0A3G5ECL4 A0A172M5U0 ENST00000264834.6 A0A385KNS9 A0A223PZB5 B7TQ30 B7TQ31 A0A0U4DXB2 B9UZC5 |